about the public meeting process should be directed to Francis Cameron; Office of the General Counsel, USNRC, Washington DC 20555–000; E-mail: *FXC@nrc.gov*; telephone: (301) 415–1642.

SUPPLEMENTARY INFORMATION:

Draft NUREG–1556, Consolidated Guidance About Materials Licenses—Volume 9, Program—Specific Guidance About Medical Use Licenses

The NRC is issuing a draft of NUREG–1556, Volume 9, for public comment for a 60-day period. In addition to obtaining written comments, the staff will be conducting a public workshop on April 25, 2002, to obtain stakeholder comments on this Volume, with emphasis on therapeutic applications of byproduct materials. A second public workshop will be held on April 30, 2002, to receive stakeholder input on guidance, with emphasis on diagnostic applications of byproduct materials. Both workshops will be held in the Auditorium at NRC Headquarters in Rockville, MD.

The NRC staff is seeking input on the guidance contained in the draft NUREG, previously published for public comment in August 1998, in order to make the guidance as useful as possible to those who may seek NRC licensure under 10 CFR part 35, ''Medical Use of Byproduct Material.'' Comments received since publication of the 1998 draft have been considered by staff; these comments and NRC's responses appear in Appendix Z of the current draft. Comments about any of the guidance in Volume 9 are welcome; staff is especially interested in receiving comments on the following questions:

1. Level of Detail and Format: Is the format and level of detail in the guidance appropriate for first-time applicants? Should the guidance be more general in describing acceptable methods of meeting 10 CFR part 35 requirements? If so, please provide suggestions for revisions. Discussion about the pros and cons of providing extensive detail about safety and other procedures would be especially helpful.

2. Model Procedures: Are the model procedures helpful as written? Should they be retained or rewritten? If so, please provide suggestions for revisions.

3. Licensing Guidance Specific to Diagnostic Nuclear Medicine: The staff is considering development of a summary of the licensing requirements for diagnostic medical use of byproduct materials? Is such a document desirable? What should be provided in the guidance? How long should it be?

4. Other Guidance: Are there additional voluntary industry consensus standards or other publically available documents that should be considered for reference in NUREG–1556, Volume 9?

To facilitate the NRC's handling of comments, we request that commenters relate their comments to specific sections and/or appendices in the NUREG. This will help place the comments in context and aid in understanding how they relate to the guidance.

The NRC is placing added emphasis on conducting its regulatory activities in a risk-informed and performance-based manner. This approach is intended to be less prescriptive and allow for the implementation of programs by licensees that may be specific to their needs while meeting the regulatory requirements. In the past, applicants have requested guidance from the NRC staff on what procedures are acceptable, with the expectation that licensing process delays would thereby be avoided. Others have expressed the view that the provision of specific guidance results in the perception that the only way to receive a license is to adhere to the guidance. The NRC staff seeks to meet the needs of applicants for licensure, while not suggesting that details in the guidance are prescriptive. Comments on Volume 9 will help NRC staff to provide guidance that is helpful while not providing too much detail.

Dated at Rockville, Maryland, this 28th day of March, 2002.

For The Nuclear Regulatory Commission

Patricia K. Holahan,

Chief, Rulemaking and Guidance Branch, Division of Industrial and Medical Nuclear Safety, Office of Nuclear Materials Safety and Safeguards.

[FR Doc. 02–8243 Filed 4–4–02; 8:45 am]

BILLING CODE 7590–01–P

SECURITIES AND EXCHANGE COMMISSION

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Filings and Information Services, Washington, DC 20549

Extension:

Rule 17f–2(e), SEC File No. 270–37; OMB Control No. 3235–0031

Notice is hereby given that pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), the Securities and Exchange Commission (''Commission'') is soliciting comments on the collection of information summarized below. The Commission plans to submit this existing collection of information to the Office of Management and Budget for extension and approval.

Rule 17f–2(e) requires members of national securities exchanges, brokers, dealers, registered transfer agents, and registered clearing agencies claiming exemption from the fingerprinting requirements of Rule 17f–2 to prepare and maintain a statement supporting their claim for exemption. Approximately 75 respondents incur an annual total burden of 37.5 hours complying with the requirements of Rule 17f–2(e).

Written comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimates of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted in writing within 60 days of this publication.

Please direct your written comments to Michael E. Bartell, Associate Executive Director, Office of Information Technology, Securities and Exchange Commission, 450 5th Street, NW, Washington, DC 20549.

Dated: March 29, 2002.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 02–8205 Filed 4–4–02; 8:45 am]

BILLING CODE 8010–01–P

SECURITIES AND EXCHANGE COMMISSION

[Release No. IC—25502]

Notice of Applications for Deregistration Under Section 8(f) of the Investment Company Act of 1940

March 29, 2002.

The following is a notice of applications for deregistration under section 8(f) of the Investment Company Act of 1940 for the month of March, 2002. A copy of each application may be obtained for a fee at the SEC's Public Reference Branch, 450 Fifth St., NW, Washington, DC 20549–0102 (tel. 202–942–8090). An order granting each